Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 2a Study of SLV213 in Ambulatory Individuals Positive for COVID-19

NCT04843787 is registered in ClinicalTrials.gov with Kenneth Krantz, MD, PhD as lead sponsor.

NCT NCT04843787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04843787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 2a Study of SLV213 in Ambulatory Individuals Positive for COVID-19
Lead sponsor
Kenneth Krantz, MD, PhD
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2023
Completion date
July 1, 2024
Enrollment
81 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid19